secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2021-12-02T23:59:59+00:00
Accession:  0001493152-21-030260
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Therapeutics appoints Mark J. Gilbert to Board, replacing Hoonmo Lee
-----------------------------------------------------------------------------

- Hoonmo Lee resigned from the Board effective Nov. 29, 2021, with no disagreement.
- Board elected Mark J. Gilbert, M.D. as Class I director, term until 2022 annual meeting.
- Dr. Gilbert is EVP of R&D at Acepodia, former CMO of Juno Therapeutics.
- Dr. Gilbert granted option to purchase 20,000 shares at $5.35/share, vesting in 1 year.
- Eligible for annual retainer of $50,000 and additional option grants at each annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315221030260/0001493152-21-030260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315221030260/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-030260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer